LPLarissa Garcia Pinto

Larissa Garcia Pinto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Larissa Garcia Pinto has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: Cytokines and Pain

    by Larissa G. Pinto, Felipe A. Pinho-Ribeiro, Waldiceu A. Verri

    Editorial on the Research Topic Cytokines and Pain Cytokines are released by immune and non-immune cells to orchestrate a great variety of physiological and disease processes. In special, cytokines can both directly and indirectly activate nociceptor sensory neurons modulating pain development. In turn, nociceptors also function as cellular regulators of the immune response in sterile and infectious diseases. All these aspects were within the aims of this Research Topic entitled “Cytokines and Pain”. There were two review articles and nine research articles published. Starting with the two reviews, they used different approaches. Vanderwall and Milligan discuss the contribution of cytokines to pain as molecules that link the immune and nervous system cells from peripheral tissues to the spinal cord (SC) triggering pain with the underlying contribution of neuroimmune interactions. Another focus of the review is the current gene therapies targeting cytokines to reduce pathological pain. Sexual dimorphism in pain and some additional inflammatory pathways are discussed. Santos et al. address the contribution of cytokines to nociceptor activation at four levels; in the peripheral tissues, at the dorsal root ganglia (DRG) in which the cellular bodies and nucleus of primary afferent neurons reside, and at spinal cord (SC) and supra-SC levels. The discussion approaches cellular interactions and role of cytokines to pain at each level. Their table one also brings a comprehensive view of cytokine families, cellular sources, and roles in pain and diseases. We organized the nine research papers in this editorial from the periphery to the CNS. Napimoga et al. investigated the inflammatory and nociceptive effects of secreted osteoclastogenic factor of activated T cells (SOFAT), a novel cytokine, in collagen-induced arthritis (CIA). The intra-articular injection of 10 ng of SOFAT induced a four days-lasting mechanical hyperalgesia. SOFAT levels were higher in joint samples of CIA mouse than naïve mouse, and in synovial samples of rheumatoid arthritis patients than in osteoarthritis patients. Thus, bringing the first insight about the role of SOFAT in pain and inflammation in arthritis. Guo et al. demonstrate that the injection of NGF in the trigeminal ganglia (TG) reduces the bite force upon tooth movement, a surrogate measure of pain. Inhibiting NGF enhanced the bite force, indicating reduced pain. NGF and tooth movement increased CGRP and CCL19 expression in the TG as well as CCL19 injection in the TG induced pain. Anti-CCL19 inhibited tooth movement pain and NGF enhanced tooth movement pain. Thus, demonstrating a novel role for CCL19 in tooth movement- and NGF-dependent pain. Gonçalves et al. asked what was maintaining pain in a model of antigen-induced monoarthritis (AIA) after articular inflammation resolution. Mechanical hyperalgesia was accompanied by c-Fos activation in the DRG by the 8th day when peripheral inflammation has already ended. At the DRG (L4 level) there was enhanced mRNA expression of TNF-α and TNFR2, and TNF-α levels. And etanercept (a soluble TNFR2) inhibited the persistent pain. Thus, DRG TNF-α and TNFR2 explain the persistent pain in AIA after peripheral inflammation resolution. Patients with Chagas disease caused by Trypanosoma cruzi report pain in the acute phase of the disease. Borghi et al. demonstrate for the first time that pain during T. cruzi infection involves the activation of DRG neurons and SC microglia and astrocytes. There is interaction of SC glial cells and neurons that via NFkB control the expression of CX3CR1, TNF-α and IL-1β since the inhibition of glial cells reduces the expression of those chemokines and cytokines both at the DRG and SC. Thus, unveiling a previously unknown mechanism of pain in T. cruzi infection. Fonseca et al. identified the cytokine IL-27 as an important endogenous mediator that counteracts the development of neuropathic pain following spared nerve injury (SNI). Peripheral nerve injury induces IL-27 expression in the SC and DRG that activates IL-27 receptor-expressing cells (macrophages, microglia, and astrocytes), thus, triggering the production of IL-10 and controlling the intensity of pain. Piotrowska et al. observed that CXCL3 and CXCR2 co-localize with neurons in the SC of naïve and chronic constriction injury (CCI) animals. And that microglia could also be a source of CXCL3 in CCI. NVP CXCR2 20 (a selective CXCR2 receptor antagonist) treatment reduced SC production of CXCL3 and satellite glial cells activation in the DRG. Primary microglial and astroglial cultures corroborated microglia would be the main source of CXCL3. Thus, CXCL3/CXCR2 signaling has a role in CCI neuropathic pain that can be targeted by NVP CXCR2 20. Nerve damage is also a key feature of multiple sclerosis (MS), an extremely debilitating neurodegenerative disease that is often accompanied by the development of chronic neuropathic pain. By analyzing the electroencephalography (EEG) of patients with central neuropathic pain and comparing the results with those from patients without neuropathic pain, Krupina et al. identified changes in the power spectral density (PSD) that were specific signatures of patients with neuropathic pain. The authors observed alterations in spectral EEG patterns and peak frequencies of MS patients with neuropathic pain, including increased PSD for the theta, beta1, and beta2 frequencies in most regions of interest. This work demonstrates the existence of putative alterations in cortical communication that are specific for MS patients with neuropathic pain and that could be the basis of the sensory dysfunction observed in these patients. The mechanisms involved in MS were also evaluated in a model of experimental autoimmune encephalomyelitis (EAE). Xiao et al. observed that HMGB1 (high mobility group box 1 protein) induced shh (sonic hedgehog) release in astrocytes culture, through RAGE (receptor for advanced glycation end-products)-mediated JNK, p38, and STAT3 phosphorylation. Furthermore, HMGB1 also promotes shh in EAE, and shh treatment was able to alleviate the progress of EAE in mice. Thus, this study suggests HMGB1/shh has a protective role in EAE. Neural pain is an important symptom in leprosy patients. In a retrospective study, Angst et al. assessed serum levels of cytokines in leprosy patients with or without pain as well as diabetic neuropathy pain. The authors observed an increased level of IL-1β, TNF, TGF-β and IL-17 in leprosy patients with neuropathic or nociceptive pain when compared with painless leprosy patients. Moreover, serum levels of IL-6 were increased in both leprosy and diabetic neuropathic pain patients, being an interesting target to control pain. IL-1β was identified as a key cytokine associated with neural leprosy pain when compared to diabetic neuropathic pain and can be used as a biomarker for patient follow-up. Concluding, the two review papers, seven research papers using animal models and two clinical research papers addressed peripheral, DRG, SC and supra-SC mechanisms focusing on cytokines and neuro-immune interaction mechanisms in pain. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. LP received funding from Versus Arthritis UK (grant 21522), Wellcome Trust UK (205006/Z/16/Z) and FAPESP/KCL Joint Grant (process number 2017/50419-9). WAVJ receives Brazilian grants from PPSUS funded by Decit/SCTIE/MS intermediated by CNPq with support of Fundação Araucária and SESA-PR (agreement 041/2017); Programa de Apoio a Grupos de Excelência (PRONEX) grant supported by SETI/Fundação Araucária and MCTI/CNPq, and Governo do Estado do Paraná (agreement 014/2017); and CNPq (#443180/2016-4; # 427946/2018-2; # 309633/2021-4; # 307186/2017-2). The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Keywords: pain, cytokine, neuro-immune communcation, microglia, astrocyte, interleukin, nociceptor, chemokine Citation: Pinto LG, Pinho-Ribeiro FA and Verri WA Jr (2021) Editorial: Cytokines and Pain. Front. Immunol. 12:788578. doi: 10.3389/fimmu.2021.788578 Received: 02 October 2021; Accepted: 05 October 2021; Published: 21 October 2021. Edited and reviewed by: Copyright © 2021 Pinto, Pinho-Ribeiro and Verri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Larissa G. Pinto, larissa_garcia.pinto@kcl.ac.uk; larifarm@gmail.com; Felipe A. Pinho-Ribeiro, felipe_ribeiro@hms.harvard.edu; Waldiceu A. Verri Jr, waldiceujr@yahoo.com.br; waverri@uel.br †ORCID: Larissa G. Pinto, orcid.org/0000-0002-3619-907X Felipe A. Pinho-Ribeiro, orcid.org/0000-0003-4264-9839 Waldiceu A. Verri Jr, orcid.org/0000-0003-2756-9283


  • Open Access

    Pharmacokinetic disposition of erythraline in rats after intravenous administration

    by Daniel P. Demarque, Daniel R. Callejon, Larissa G. Pinto, Dayana R. Gouvea, Natália V. de Moraes, José N.C. Lopes, Norberto P. Lopes, Thais Guaratini


  • Mechanisms underlying the hyperalgesic responses triggered by joint activation of TLR4

    by Ana T.G. Guerrero, Larissa G. Pinto, Fernando Q. Cunha, Sérgio H. Ferreira, Jose C. Alves-Filho, Waldiceu A. Verri, Thiago M. Cunha

    Toll-like receptors (TLRs) including TLR4 and their signal pathways contribute to the pathogenesis of arthritis. Herein, we evaluated the mechanisms underlying the hyperalgesic response caused by TLR4 activation in the tibio-tarsal joint in mice. Joint inflammatory hyperalgesia was induced by intra-articular (ia) injection of LPS (lipopolysaccharide- TLR4 agonist) in C57BL/6, TLR4, TLR2, MyD88, TRIF, TNFR1/2 and IL-1R1 knockout (-/-) mice. Joint hyperalgesia was evaluated using an electronic von Frey. Neutrophil recruitment was assessed by MPO activity. Joint levels of cytokines were measured by ELISA. Firstly, it was shown that LPS injected into the joints causes a dose- and time-dependent reduction in the mechanical nociceptive threshold. The TLR4 activation in the joint triggers mechanical hyperalgesia and neutrophil migration, which was abolished in TLR4 -/- and MyD88-/-, but not in TLR2-/- and TRIF-/- mice. Besides, joint administration of LPS increased the release of TNF-α, IL-1β, and KC/CXCL1, which were reduced in TLR4-/- and MyD88-/-, but not in TRIF-/- mice. In agreement, the LPS-induced joint nociceptive effect was decreased in TNFR1/2-/- and IL-1R1-/- mice or in mice pre-treated with a CXCR1/2 selective antagonist (DF2156A). These results suggest that TLR4 activation in the joint produces articular hyperalgesia via MyD88 signaling pathway. Moreover, this pathway is involved in the cascade of events of articular hyperalgesia through mechanisms dependent on cytokines and chemokines production. Thus, TLR4/MyD88 signaling pathway inhibitors might be useful for the treatment of inflammatory joint pain.


  • Pharmacokinetic properties, in vitro metabolism and plasma protein binding of govaniadine an alkaloid isolated from Corydalis govaniana Wall

    by Lucas M.M. Marques, Daniel R. Callejon, Larissa G. Pinto, Michel L. de Campos, Anderson R.M. de Oliveira, Ricardo Vessecchi, Achyut Adhikari, Ram L.S. Shrestha, Rosangela G. Peccinini, Norberto P. Lopes


  • Neutrophil Recruitment and Articular Hyperalgesia in Antigen‐Induced Arthritis are Modulated by the Cholinergic Anti‐Inflammatory Pathway

    by Alexandre Kanashiro, Jhimmy Talbot, Raphael S. Peres, Larissa G. Pinto, Gabriel S. Bassi, Thiago M. Cunha, Fernando Q. Cunha

    The cholinergic anti‐inflammatory pathway (CAP) is a complex neuroimmune mechanism triggered by the central nervous system to regulate peripheral inflammatory responses. Understanding the role of CAP in the pathogenesis of rheumatoid arthritis (RA) could help develop new therapeutic strategies for this disease. Therefore, we investigated the participation of this neuroimmune pathway on the progression of experimental arthritis. Using antigen‐induced arthritis (AIA) model, we investigated in mice the effects of vagotomy or the pharmacological treatments with hexamethonium (peripheral nicotinic receptor antagonist), methylatropine (peripheral muscarinic receptor antagonist) or neostigmine (peripheral acetylcholinesterase inhibitor) on AIA progression. Unilateral cervical vagotomy was performed 1 week before the immunization protocol with methylated bovine serum albumin (mBSA), while drug administration was conducted during the period of immunization. On day 21, 6 hr after the challenge with mBSA injection in the femur–tibial joint, the local neutrophil migration and articular mechanical hyperalgesia were assessed. Herein, we observed that vagotomy or blockade of peripheral nicotinic (but not muscarinic) receptors exacerbated the clinical parameters of this disease. Moreover, peripheral acetylcholinesterase inhibition by neostigmine treatment promoted a reduction of neutrophil recruitment in the knee joint and articular hyperalgesia. Our results demonstrated that peripheral activation of CAP modulates experimental arthritis, providing a pre‐clinical evidence of a potential therapeutic strategy for RA.


  • Open Access

    Dynamic weight bearing is an efficient and predictable method for evaluation of arthritic nociception and its pathophysiological mechanisms in mice

    by Andreza U. Quadros, Larissa G. Pinto, Miriam M. Fonseca, Ricardo Kusuda, Fernando Q. Cunha, Thiago M. Cunha

    The assessment of articular nociception in experimental animals is a challenge because available methods are limited and subject to investigator influence. In an attempt to solve this problem, the purpose of this study was to establish the use of dynamic weight bearing (DWB) as a new device for evaluating joint nociception in an experimental model of antigen-induced arthritis (AIA) in mice. AIA was induced in Balb/c and C57BL/6 mice and joint nociception was evaluated by DWB. Western Blotting and real-time PCR were used to determine protein and mRNA expression, respectively. DWB detected a dose- and time-dependent increase in joint nociception during AIA and was able to detect the dose-response effects of different classes of analgesics. Using DWB, it was possible to evaluate the participation of spinal glial cells (microglia and astrocytes) and cytokines (IL-1β and TNFα) for the genesis of joint nociception during AIA. In conclusion, the present results indicated that DWB is an effective, objective and predictable test to study both the pathophysiological mechanisms involved in arthritic nociception in mice and for evaluating novel analgesic drugs against arthritis.


  • Open Access

    Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway

    by Flávio P. Veras, Raphael S. Peres, André L. L. Saraiva, Larissa G. Pinto, Paulo Louzada-Junior, Thiago M. Cunha, Jonas A. R. Paschoal, Fernando Q. Cunha, José C. Alves-Filho

    Fructose 1,6-bisphosphate (FBP) is an endogenous intermediate of the glycolytic pathway. Exogenous administration of FBP has been shown to exert protective effects in a variety of ischemic injury models, which are attributed to its ability to sustain glycolysis and increase ATP production. Here, we demonstrated that a single treatment with FBP markedly attenuated arthritis, assessed by reduction of articular hyperalgesia, joint swelling, neutrophil infiltration and production of inflammatory cytokines, TNF and IL-6, while enhancing IL-10 production in two mouse models of arthritis. Our mechanistic studies showed that FBP reduces joint inflammation through the systemic generation of extracellular adenosine and subsequent activation of adenosine receptor A2a (A2aR). Moreover, we showed that FBP-induced adenosine generation requires hydrolysis of extracellular ATP through the activity of the ectonucleosides triphosphate diphosphohydrolase-1 (ENTPD1, also known as CD39) and ecto-5′-nucleotidase (E5NT, also known as CD73). In accordance, inhibition of CD39 and CD73 abolished anti-arthritic effects of FBP. Taken together, our findings provide a new insight into the molecular mechanism underlying the anti-inflammatory effect of FBP, showing that it effectively attenuates experimental arthritis by activating the anti-inflammatory adenosinergic pathway. Therefore, FBP may represent a new therapeutic strategy for treatment of rheumatoid arthritis (RA).


  • Open Access

    Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production

    by Larissa G. Pinto, Jhimmy Talbot, Raphael S. Peres, Rafael F. Franca, Sérgio H. Ferreira, Bernhard Ryffel, José Carlos F. Aves-Filho, Florêncio Figueiredo, Thiago M. Cunha, Fernando Q. Cunha

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by neutrophil articular infiltration, joint pain and the progressive destruction of cartilage and bone. IL-22 is a key effector molecule that plays a critical role in autoimmune diseases. However, the function of IL-22 in the pathogenesis of RA remains controversial. In this study, we investigated the role of IL-22 in the early phase of antigen-induced arthritis (AIA) in mice. AIA was induced in C57BL/6, IL-22−/−, ASC−/− and IL-1R1−/− immunized mice challenged intra-articularly with methylated bovine serum albumin (mBSA). Expression of IL-22 in synovial membranes was determined by RT-PCR. Articular hypernociception was evaluated using an electronic von Frey. Neutrophil recruitment and histopathological analyses were assessed in inflamed knee joint. Joint levels of inflammatory mediators and mBSA-specific IgG concentration in the serum were measured by ELISA. The IL-22 mRNA expression and protein levels in synovial tissue were increased during the onset of AIA. In addition, pharmacological inhibition (anti-IL-22 antibody) and genetic deficiency (IL-22−/− mice) reduced articular pain and neutrophil migration in arthritic mice. Consistent with these findings, recombinant IL-22 joint administration promoted articular inflammation per se in WT mice, restoring joint nociception and neutrophil infiltration in IL-22−/− mice. Moreover, IL-22-deficient mice showed reduced synovitis (inflammatory cell influx) and lower joint IL-1β levels, whereas the production of IL-17, MCP-1/CCL2, and KC/CXCL1 and the humoral immune response were similar, compared with WT mice. Corroborating these results, the exogenous administration of IL-22 into the joints induced IL-1β production in WT mice and reestablished IL-1β production in IL-22−/− mice challenged with mBSA. Additionally, IL-1R1−/− mice showed attenuated inflammatory features induced by mBSA or IL-22 challenge. Articular nociception and neutrophil migration induced by IL-22 were also reduced in ASC−/− mice. These results suggest that IL-22 plays a pro-inflammatory/pathogenic role in the onset of AIA through an ASC-dependent stimulation of IL-1β production.


  • Expression and activity ofNOD1andNOD2/RIPK2signalling in mononuclear cells from patients with rheumatoid arthritis

    by Rfo Franca, Sm Vieira, J Talbot, Rs Peres, Lg Pinto, Ds Zamboni, P Louzada-Junior, Fq Cunha, Tm Cunha

    Objectives: The aim of this study was to analyse the expression and function of nucleotide-binding oligomerization domain (NOD)1 and NOD2 in isolated cells of patients with rheumatoid arthritis (RA). Method: mRNA expression levels of NOD1, NOD2, and receptor-interacting serine/threonine kinase 2 (RIPK2) genes were determined by quantitative polymerase chain reaction (qPCR) in peripheral blood mononuclear cells (PBMCs) and synovial fluid T cells (SFTCs) isolated from RA and osteoarthritis (OA) patients. Cytokines were measured by enzyme-linked immunosorbent assay (ELISA) in plasma and cell culture supernatants. The stimulatory effect of RA SF was assessed by an in-vitro NOD2 activation assay using nuclear factor kappa B (NF-κB) luciferase-transfected cells. Results: A significantly higher level of NOD2 and RIPK2 mRNA expression, but not NOD1, was observed on PBMCs and SFTCs isolated from RA patients compared to the OA control group. In addition, the NOD2 pathway up-regulation was functional, as stimulation of PBMCs with muramyl dipeptide (MDP) induced the production of higher amounts of tumour necrosis factor (TNF)-α, interleukin (IL)-8, and IL-1β compared with OA PBMCs. Incubation of PBMCs from healthy donors with recombinant TNF-α or RA serum induced the expression of NOD2 mRNA. Finally, SF isolated from RA patients is able to activate the NF-κB signalling pathway in HEK293T-transfected cells in a NOD2-dependent manner. Conclusions: Our findings suggest that NOD2/RIPK2 signalling is up-regulated in immune cells of RA patients. Moreover, it seems that there is a NOD2 agonist in the SF of RA patients. Therefore, NOD2/RIPK2 activation can modulate the innate immune response and may play a role in the perpetuation of the inflammatory response in RA.


  • Open Access

    CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis

    by Jhimmy Talbot, Francine J. Bianchini, Danilele C. Nascimento, Rene D. R. Oliveira, Fabricio O. Souto, Larissa G. Pinto, Raphael S. Peres, Jaqueline R. Silva, Sergio C. L. Almeida, Paulo Louzada‐Junior, et al.

    Objective: Infiltration of neutrophils into the joints plays an important role in bone erosion and articular destruction in rheumatoid arthritis (RA). Neutrophil trafficking during inflammation is a process that involves activation of chemotactic receptors. Recent findings suggest that changes in chemotactic receptor patterns could occur in neutrophils under certain inflammatory conditions. The aim of this study was to evaluate the gain of responsiveness of neutrophils to CCL2 in RA patients and to assess the role of CCL2 in driving neutrophil infiltration into the joints.Methods: Neutrophils were purified from the peripheral blood of patients with RA or from mice with antigen‐induced arthritis (AIA). Expression of CCR2 was evaluated using polymerase chain reaction, flow cytometry, and immunofluorescence analyses. In vitro chemotaxis to CCL2 was assayed to evaluate the functional significance of de novo CCR2 expression. The murine AIA model was used to evaluate the in vivo role of CCR2 in neutrophil infiltration into the joints.Results: High CCR2 expression and responsiveness to CCL2 were observed in neutrophils from the blood of patients with early RA and in neutrophils from the blood and bone marrow of mice with AIA. Genetic deficiency or pharmacologic inhibition of CCR2 protected against the infiltration of neutrophils into the joints. This protection was not associated with an impairment of the neutrophil chemotactic ability or CXC chemokine production in the joints. Moreover, adoptive transfer of wild‐type mouse neutrophils to CCR2‐deficient mice restored neutrophil infiltration and the articular mechanical hyperalgesia associated with joint inflammation.Conclusion: These findings suggest that CCR2 is directly involved in the detrimental infiltration of neutrophils into the joints in patients with RA, showing a new inflammatory role of CCR2 during RA flares or active disease.